The U.S. Food and Drug Administration (FDA) will host a series of four webinars on the Infant Formula Transition Plan for Exercise of Enforcement Discretion.

The U.S. Food and Drug Administration (FDA) will continue providing flexibility to infant formula manufacturers under certain conditions in an effort to stabilize U.S. product supplies. 

The U.S. Food and Drug Administration (FDA) has concluded its internal review of the agency’s response to the U.S. infant formula supply crisis, which details key findings and recommendations that will allow the agency to respond more quickly during food safety emergencies.

To mitigate future infant formula supply disruptions and food safety incidents, a U.S. Senate Committee passed an act that establishes new requirements for the U.S Food and Drug Administration (FDA) regarding formula regulation. 

The U.S. Food and Drug Administration (FDA) held a webinar to clarify its recent Guidance for Industry on Infant Formula Enforcement Discretion Policy, which is part of FDA’s efforts to mitigate the infant formula shortage in the U.S.

Safe Food for Infants in the EU and China (SAFFI) recently published three papers that lay new groundwork for advancing global infant food safety.

In light of the current infant formula supply shortage, the U.S. Food and Drug Administration (FDA) will enter a consent decree with Abbott Nutrition that will allow the company to resume production of formula products at its Sturgis, Michigan facility. FDA also released a guidance that will allow formula manufacturers and importers greater flexibility.

The U.S. Food and Drug Administration (FDA) has been working to increase the supply of infant and specialty formula products in the U.S., including working with Abbott Nutrition, the subject of a recent foodborne illness outbreak and subsequent recall.

The U.S. Food and Drug Administration (FDA) is investigating cases concerning powdered infant formula, as it may have caused Cronobacter sakazakii and Salmonella Newport infections.